US5036102A
Expired / Lapsed
US
⏱️ 0.0 years remaining
Method of treating autoimmune diseases comprising administration of psoralen dosage forms
Assignee: Therakos Inc
•
Filing: 1990-09-14
•
Granted: 1991-07-30
•
Expires: 2010-09-14
Abstract
Abstract A method of treating leukocyte mediated autoimmune and skin diseases using psoralen reagent composition comprising sterile aqueous solutions suitable for extracorporeal administration to blood from a subject being treated by ultraviolet-A photophoresis.
Inventors
- 👤 Maria O. Bachynsky
- 👤 Martin H. Infeld
- 👤 Richard J. Margolis
- 👤 Dennis A. Perla
Bibliographic Details
Application Number
—
Jurisdiction
US
Data Source
google_patents
Last Synchronized
2026-10-25 17:09
CPC Classifications
A; A61; A61K; A61K31/00; A61K31/33; A61K31/335; A61K31/365; A61K47/00; A61K47/06; A61K47/08; A61K47/10; A61K9/00; A61K9/0012; A61K9/0014; A61P; A61P29/00
Claims Analysis
Total Claims: 5
Claim 1
Independent Claim
65 words
A method for the therapy of leukocyte mediated diseases comprising extracorporeal administration to the blood of a subject undergoing ultraviolet-A photophoresis prior to reinfusion of the blood into said subject a composition comprising a sterile aqueous solution of about 0.005 mg/ml to about 1 mg/ml of a psoralen, ethyl alcohol, propylene glycol and water, said composition having a pH from about 2.0 to about 5.5.
Claim 2
Independent Claim
65 words
A method for the therapy of leukocyte mediated diseases comprising extracorporeal administration to the blood of a subject undergoing ultraviolet-A photophoresis prior to reinfusion of the blood into said subject a composition comprising a sterile aqueous solution of about 0.005 mg/ml to about 1 mg/ml of a psoralen, ethyl alcohol, propylene glycol and water, said composition having a pH from about 2.0 to about 5.5.
Claim 3
Dependent Claim
32 words
The method of claim 1 wherein the leukocyte mediated condition is selected from the group consisting of Scleroderma, Systemic Lupus Erythematosis (SLE) Psoriasis, Pemphigus, Psoriatic Arthritis, Atopic Dermatitis, Rheumatoid Arthritis, Multiple Sclerosis.
Claim 4
Dependent Claim
10 words
The method of claim 1 wherein the psoralen is 8-MOP.
Claim 5
Dependent Claim
34 words
The method of claim 3 wherein the 8-MOP is administered to the patient's blood just after it is withdrawn from the patient and prior to its separation into leukocyte rich and leukocyte poor fractions.
References Cited (Backward Citations)
US4147703A
Cited
GB2052980A
Cited
US4913901A
Cited
US4321919A
Cited
US4454152A
Cited
US4612007A
Cited
US4613322A
Cited
US4684521A
Cited
US4683889A
Cited
US4727027A
Cited
US4826967A
Cited
USPTO Annuity & Maintenance Windows
| Annuity Stage | Window Opens | Payment Deadline | Surcharge Period Until | Estimated Fee | Status |
|---|---|---|---|---|---|
| 3.5 Years (Year 4) | 1994-07-29 | 1995-01-28 | 1995-07-30 | $2000.00 | Window Closed / Lapsed |
| 7.5 Years (Year 8) | 1998-07-29 | 1999-01-28 | 1999-07-30 | $3760.00 | Window Closed / Lapsed |
| 11.5 Years (Year 12) | 2002-07-29 | 2003-01-28 | 2003-07-30 | $7700.00 | Window Closed / Lapsed |